Skip to main content
Erschienen in: Medical Oncology 3/2011

01.09.2011 | Original Paper

Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years?

verfasst von: Gul Basaran, Cabuk Devrim, Hale B. Caglar, Bahadır Gulluoglu, Handan Kaya, Selcuk Seber, Taner Korkmaz, Ferhat Telli, Muharrem Kocak, Faysal Dane, Fulden P. Yumuk, Serdar N. Turhal

Erschienen in: Medical Oncology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

It has been shown that breast cancer patients with N3a (10 positive lymph nodes) had a poor prognosis. We planned to investigate the clinical outcome BC patients who presented with N3a disease and had no evidence of systemic metastasis at the time of diagnosis. We made a retrospective chart review of breast cancer patients who had ≥10 positive lymph nodes and received adjuvant systemic therapy in Marmara University Hospital between 1998 and 2008. We recorded clinical, pathologic and treatment characteristics of the patients and analyzed the survival outcome. We identified 73 patients with N3a disease who were treated in Marmara University Hospital between 1998 and 2008. The median age was 52. Most (75%) of the patients had invasive ductal histology, 75% had T2/T3 tumors, 36% had grade 3 tumors. The median number of metastatic lymph nodes was 15. Estrogen and progesterone receptors were both positive in 61% and both negative in 16+ tumors. Her-2/neu status was assessed in 68% of the tumors; 18% of patients had 3+ and 50% had negative scores. Six patients had triple negative tumors. All patients except one received adjuvant chemotherapy and radiotherapy. Seventy-four percent of patients received anthracycline/taxane-based chemotherapy. Fifty-nine patients received adjuvant endocrine therapy, 42% them received aromatase inhibitors. Five of the 13 Her-2 positive patients received adjuvant trastuzumab. With a median follow-up of 47 months, 5-year disease and overall survival rates were 66 and 81%, respectively. Twenty-four patients had relapsed and 14 patients died. Her-2 status and the number of lymph nodes (<20 vs. ≥20) had significant impact on disease-free survival in the univariate analysis (P = 0.03 and 0.05, respectively) and Her-2 retained its significant impact on disease-free survival in the multivariate analysis (P = 0.05). The prognosis of BC patients with N3a disease has changed favorably in the past decade with the current standards of care.
Literatur
1.
Zurück zum Zitat van ‘t Veer LJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6.CrossRef van ‘t Veer LJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6.CrossRef
2.
Zurück zum Zitat van de Vijver MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009.PubMedCrossRef van de Vijver MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009.PubMedCrossRef
3.
Zurück zum Zitat Carter CL, Allen C, DE Henson. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181–7.PubMedCrossRef Carter CL, Allen C, DE Henson. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181–7.PubMedCrossRef
4.
Zurück zum Zitat Nemoto T, et al. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980;45(12):2917–24.PubMedCrossRef Nemoto T, et al. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980;45(12):2917–24.PubMedCrossRef
5.
Zurück zum Zitat Singletary SE, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20(17):3628–36.PubMedCrossRef Singletary SE, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20(17):3628–36.PubMedCrossRef
6.
Zurück zum Zitat Early Breast Cancer Trialists’ CollaborativeGroup (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRef Early Breast Cancer Trialists’ CollaborativeGroup (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRef
7.
Zurück zum Zitat Bria E, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer. Cancer. 2006;106:2337–44.PubMedCrossRef Bria E, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer. Cancer. 2006;106:2337–44.PubMedCrossRef
8.
Zurück zum Zitat De Laurentiis M, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26:44–53.PubMedCrossRef De Laurentiis M, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26:44–53.PubMedCrossRef
9.
Zurück zum Zitat Ferguson T, et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007; Issue 4. Ferguson T, et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007; Issue 4.
10.
Zurück zum Zitat Walker MS, et al. The natural history of breast cancer with more than 10 positive nodes. Am J Surg. 1995;169:575–9.PubMedCrossRef Walker MS, et al. The natural history of breast cancer with more than 10 positive nodes. Am J Surg. 1995;169:575–9.PubMedCrossRef
11.
Zurück zum Zitat Buzdar AU, et al. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer. 1992;69(2):448–52.PubMedCrossRef Buzdar AU, et al. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer. 1992;69(2):448–52.PubMedCrossRef
12.
Zurück zum Zitat Schmoor C, Sauerbrei W, Bastert G, Bojar H, Schumacher M, German Breast Cancer Study Group. Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer. 2001;37(9):1123–31.PubMedCrossRef Schmoor C, Sauerbrei W, Bastert G, Bojar H, Schumacher M, German Breast Cancer Study Group. Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer. 2001;37(9):1123–31.PubMedCrossRef
13.
Zurück zum Zitat Peters WP, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA–13. J Clin Oncol. 2005;23:2191.PubMedCrossRef Peters WP, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA–13. J Clin Oncol. 2005;23:2191.PubMedCrossRef
14.
Zurück zum Zitat Tallman MS, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003;349:17.PubMedCrossRef Tallman MS, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003;349:17.PubMedCrossRef
15.
Zurück zum Zitat Zander AR, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol. 2004;22:2273.PubMedCrossRef Zander AR, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol. 2004;22:2273.PubMedCrossRef
16.
Zurück zum Zitat Fumoleau P, et al. Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes. J Clin Oncol. 2001;19(3):612–20.PubMed Fumoleau P, et al. Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes. J Clin Oncol. 2001;19(3):612–20.PubMed
17.
Zurück zum Zitat Eiermann W, German Adjuvant Breast Cancer Group, et al. Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93)–the German Adjuvant Breast Cancer Group. Eur J Cancer. 2010;46(1):84–94.PubMedCrossRef Eiermann W, German Adjuvant Breast Cancer Group, et al. Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93)–the German Adjuvant Breast Cancer Group. Eur J Cancer. 2010;46(1):84–94.PubMedCrossRef
18.
Zurück zum Zitat Tsuchiya A, Kanno M, Abe R. The impact of lymph node metastases on the survival of breast cancer patients with ten or more positive lymph nodes. Surg Today. 1997;27(10):902–6.PubMedCrossRef Tsuchiya A, Kanno M, Abe R. The impact of lymph node metastases on the survival of breast cancer patients with ten or more positive lymph nodes. Surg Today. 1997;27(10):902–6.PubMedCrossRef
19.
Zurück zum Zitat Faneyte IF, et al. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res. 2004;10(13):4457–63.PubMedCrossRef Faneyte IF, et al. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res. 2004;10(13):4457–63.PubMedCrossRef
20.
Zurück zum Zitat Diab SG, et al. Radiation therapy, survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998;16(5):1655–60.PubMed Diab SG, et al. Radiation therapy, survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998;16(5):1655–60.PubMed
21.
Zurück zum Zitat Gianni AM, et al. Efficacy, toxicity, applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol. 1997;15(6):2312–21.PubMed Gianni AM, et al. Efficacy, toxicity, applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol. 1997;15(6):2312–21.PubMed
22.
Zurück zum Zitat Peters WP, et al. High-dose chemotherapy, autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993;11(6):1132–43.PubMed Peters WP, et al. High-dose chemotherapy, autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993;11(6):1132–43.PubMed
23.
Zurück zum Zitat Crump M, Goss PE, Prince M, Girouard C. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer, 10 or more positive axillary lymph nodes. J Clin Oncol. 1996;14(1):66–9.PubMed Crump M, Goss PE, Prince M, Girouard C. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer, 10 or more positive axillary lymph nodes. J Clin Oncol. 1996;14(1):66–9.PubMed
24.
Zurück zum Zitat Peto R, et al., Early Breast Cancer Trialists’ Collaborative Group. The worldwide overview: new results for systemic adjuvant therapies. San Antonio breast cancer symposium. 2007. Abstr P–1. Peto R, et al., Early Breast Cancer Trialists’ Collaborative Group. The worldwide overview: new results for systemic adjuvant therapies. San Antonio breast cancer symposium. 2007. Abstr P–1.
25.
Zurück zum Zitat Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431–9.PubMedCrossRef Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431–9.PubMedCrossRef
26.
Zurück zum Zitat Hudis C. CAGB 9344/CAGB C9741: what we have learnt? Eur J Cancer. 2006;Supp 4(5):10–2. Hudis C. CAGB 9344/CAGB C9741: what we have learnt? Eur J Cancer. 2006;Supp 4(5):10–2.
27.
Zurück zum Zitat Ignatiadis M, Desmedt C, Sotiriou C, de Azambuja E, Piccart M. HER-2 as a target for breast cancer therapy. Clin Cancer Res. 2009;15(6):1848–52.PubMedCrossRef Ignatiadis M, Desmedt C, Sotiriou C, de Azambuja E, Piccart M. HER-2 as a target for breast cancer therapy. Clin Cancer Res. 2009;15(6):1848–52.PubMedCrossRef
28.
Zurück zum Zitat Jabro G, et al. The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or =10 positive axillary nodes. Int J Radiat Oncol Biol Phys. 1999;44(2):273–80.PubMedCrossRef Jabro G, et al. The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or =10 positive axillary nodes. Int J Radiat Oncol Biol Phys. 1999;44(2):273–80.PubMedCrossRef
29.
Zurück zum Zitat Dowsett M, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509–18.PubMedCrossRef Dowsett M, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509–18.PubMedCrossRef
30.
Zurück zum Zitat Sørlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–74.PubMedCrossRef Sørlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–74.PubMedCrossRef
Metadaten
Titel
Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years?
verfasst von
Gul Basaran
Cabuk Devrim
Hale B. Caglar
Bahadır Gulluoglu
Handan Kaya
Selcuk Seber
Taner Korkmaz
Ferhat Telli
Muharrem Kocak
Faysal Dane
Fulden P. Yumuk
Serdar N. Turhal
Publikationsdatum
01.09.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9516-1

Weitere Artikel der Ausgabe 3/2011

Medical Oncology 3/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.